Prof C Michael Gibson

Prof C. Michael Gibson

Prof Gibson is an interventional cardiologist and professor of Medicine at Harvard. He is CEO of the non-profit Baim and PERFUSE research institutes (formerly Harvard Clinical Research Institute) which over 30 years have conducted over 1,250 studies, 100 FDA submissions, 144 NEJM papers and have over 125 ongoing trials involving 100,000 patients at present. Prof Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuated in approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices. He has directed cath labs, CCUs, served as a Chief of Cardiology & Vice Chairman of medicine.